Tipsheet
What matters at India’s listed companies
Earnings · Hospital & Healthcare · Large cap

KIMS plans ₹1,500 cr QIP as profit slides 69% on expansion drag

Revenue grew 35% to ₹1,084 cr, but new units in Bangalore, Thane, and Nasik burned ₹32 cr in EBITDA this quarter.

1 earlier story on Krishna Institute of Medical Sciences Ltd
Mkt cap₹33,405 cr
P/E138.38×
ROE17.99%
Debt / eq.0.89
₹33 cr Consolidated PAT for Q4 FY26, down from ₹106 cr a year ago.

What's new

  • Board approved a ₹1,500 cr QIP to trim a debt pile exceeding ₹3,000 cr.
  • New hospitals contributed ₹224 cr in revenue but posted an aggregate EBITDA loss of ₹32 cr.
  • Management targets break-even for new units within 12-18 months, pending insurance approvals.

Why this matters

The company is in an aggressive growth phase where revenue gains are currently eclipsed by the high cost of new hospital ramp-ups. The QIP is a necessary move to reset a balance sheet carrying over ₹3,000 crore in debt as the firm builds out its footprint across five states.

What we're watching

  • Timeline and pricing of the ₹1,500 cr QIP.
  • Progress on insurance empanelment for the Bangalore, Thane, and Nasik units.
  • Whether EBITDA margins can recover from their current 19.9% level.

The full read

Krishna Institute of Medical Sciences (KIMS) finished Q4 FY26 with a stark disconnect between top-line growth and bottom-line health. While revenue climbed 35% to ₹1,084 crore, profit plunged 69% to ₹33 crore as the company absorbed an EBITDA loss of ₹32 crore from its recently opened hospitals in Bangalore, Thane, and Nasik. These new units represent a significant drag on margins, which slipped to 19.9% this quarter. To clear the runway for expansion into Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana, KIMS is tapping the market for a ₹1,500 crore QIP. The priority is to deleverage a balance sheet burdened by over ₹3,000 crore in debt. Management expects the new hospitals to turn profitable within 12-18 months, though success hinges entirely on securing insurance empanelment. Until those approvals land, the high overheads of the expansion strategy will continue to weigh on the company's profitability.

Mentioned: KIMS · ₹1,500 cr QIP · ₹3,000 cr debt
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Krishna Institute of Medical Sciences Ltd

Hospitals
₹33,412 cr
P/E 138.41×

Latest quarter · Mar 2026

Sales₹1,075 cr
Net profit₹31 cr
Op. margin+19.2%
EPS₹1.06

Strength & growth

Debt / equity0.89×
Current ratio0.83×
Financials via Tijori — a research aid, not investment advice.KIMS on Tijori

Story so far

All notes on KIMS →
  1. 22 May 2026 · 2:40 PM IST KIMS plans ₹1,500 cr QIP as profit slides 69% on expansion drag
  2. 28d ago KIMS promoters inject ₹600 cr via warrants to retire debt, fund expansion